US: FDA says no to psychedelic MDMA as PTSD treatment
A US company seeking to use MDMA capsules to treat post-traumatic stress disorder has said federal regulators rejected the bid. Lykos Therapeutics said the FDA requested an additional Phase 3 trial to gather more data.